| Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NCT02101775) | National Cancer Institute (NCI) | 2014-07-21 |
| TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors (NCT02142803) | National Cancer Institute (NCI) | 2014-05-20 |
| Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer (NCT02111941) | Mayo Clinic | 2014-04-14 |
| Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer (NCT01275664) | Gynecologic Oncology Group | 2011-06-01 |
| TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer (NCT01294293) | Gynecologic Oncology Group | 2011-03-01 |
| Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors (NCT01233505) | National Cancer Institute (NCI) | 2010-10-01 |
| Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (NCT01074411) | National Cancer Institute (NCI) | 2010-04-05 |
| Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy (NCT01080521) | Gynecologic Oncology Group | 2010-04-01 |
| Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin (NCT00993616) | National Cancer Institute (NCI) | 2009-12-01 |
| Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer (NCT00814086) | Gynecologic Oncology Group | 2009-02-01 |
| Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy (NCT00466960) | University of Washington | 2006-05-01 |
| Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer (NCT00357448) | University of Washington | 2005-04-01 |
| Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer (NCT00079430) | National Cancer Institute (NCI) | 2004-06-01 |
| Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) (NCT00085358) | National Cancer Institute (NCI) | 2004-05-01 |
| Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma (NCT00059787) | National Cancer Institute (NCI) | 2003-04-01 |
| Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer (NCT00060359) | Gynecologic Oncology Group | 2003-04-01 |
| Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer (NCT00004221) | Gynecologic Oncology Group | 1999-11-01 |
| Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer (NCT00002913) | National Cancer Institute (NCI) | 1996-12-01 |